Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma : A Systematic Review and Meta-Analysis
Background: chemotherapy response score (CRS) is widely used to assess the response of ovarian high-grade serous carcinoma (HGSC) to chemotherapy and is based on pathological examination of omental specimens. We aimed to assess the prognostic value of CRS assessed on the uterine adnexa. Methods: a systematic review and meta-analysis were performed by searching three electronic databases from 2015 inception to September 2021. We included all studies reporting either hazard ratio (HR) with 95% confidence interval (CI) for progression-free survival (PFS) or primary PFS data, for both adnexal and omental CRS in HGSC. HRs with 95% CI were extracted and pooled by using a significant p-value < 0.05. Statistical heterogeneity was assessed by using Higgins’ I2. Results: six studies with 691 HGSC patients were included. Adnexal CRS3 vs. CRS1-2 significantly stratified PFS, with a HR of 0.572 (0.447−0.733; p < 0.001). Omental CRS3 vs. CRS1-2 significantly stratified PFS with a similar HR (HR = 0.542; 95% CI 0.444−0.662; p < 0.001). Statistical heterogeneity was 0% in both analyses. Conclusions: adnexal CRS significantly stratifies PFS in HGSC and might be used when omental CRS is not assessable.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Diagnostics (Basel, Switzerland) - 12(2022), 3 vom: 04. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Santoro, Angela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CRS |
|---|
| Anmerkungen: |
Date Revised 08.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/diagnostics12030633 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338584765 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338584765 | ||
| 003 | DE-627 | ||
| 005 | 20231226001012.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/diagnostics12030633 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338584765 | ||
| 035 | |a (NLM)35328186 | ||
| 035 | |a (PII)633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Santoro, Angela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma |b A Systematic Review and Meta-Analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background: chemotherapy response score (CRS) is widely used to assess the response of ovarian high-grade serous carcinoma (HGSC) to chemotherapy and is based on pathological examination of omental specimens. We aimed to assess the prognostic value of CRS assessed on the uterine adnexa. Methods: a systematic review and meta-analysis were performed by searching three electronic databases from 2015 inception to September 2021. We included all studies reporting either hazard ratio (HR) with 95% confidence interval (CI) for progression-free survival (PFS) or primary PFS data, for both adnexal and omental CRS in HGSC. HRs with 95% CI were extracted and pooled by using a significant p-value < 0.05. Statistical heterogeneity was assessed by using Higgins’ I2. Results: six studies with 691 HGSC patients were included. Adnexal CRS3 vs. CRS1-2 significantly stratified PFS, with a HR of 0.572 (0.447−0.733; p < 0.001). Omental CRS3 vs. CRS1-2 significantly stratified PFS with a similar HR (HR = 0.542; 95% CI 0.444−0.662; p < 0.001). Statistical heterogeneity was 0% in both analyses. Conclusions: adnexal CRS significantly stratifies PFS in HGSC and might be used when omental CRS is not assessable | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CRS | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a high grade serous carcinoma | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a prognosis | |
| 700 | 1 | |a Travaglino, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Inzani, Frediano |e verfasserin |4 aut | |
| 700 | 1 | |a Straccia, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Arciuolo, Damiano |e verfasserin |4 aut | |
| 700 | 1 | |a Valente, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a D'Alessandris, Nicoletta |e verfasserin |4 aut | |
| 700 | 1 | |a Scaglione, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Angelico, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Piermattei, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Cianfrini, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Raffone, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Zannoni, Gian Franco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostics (Basel, Switzerland) |d 2011 |g 12(2022), 3 vom: 04. März |w (DE-627)NLM250111136 |x 2075-4418 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:3 |g day:04 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/diagnostics12030633 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 3 |b 04 |c 03 | ||